Clinical trials: HCC
Hepatocellular Carcinoma
Percutaneous Radiofrequency Ablation Versus Repeat Hepatectomy for Recurrent Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world. Partial hepatectomy is still considered as the conventional therapy for HCC.
- Trial name
- NCT01570166
- Testing
- HR, RFA
- Where
- China
- Volunteers
- 210 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
SHR-1210 Plus Apatinib in Patients With Hepatocellular Carcinoma After Surgery
SHR-1210 is a humanized anti-PD1 Immunoglobulin G4 (IgG4) monoclonal antibody. This is an open- label，single center ，non-randomized ，Single Arm Exploratory Study .
- Trial name
- NCT03722875
- Testing
- SHR-1210, apatinib
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Shanghai Zhongshan Hospital
Hepatocellular Carcinoma
CT/MR-US Automatic Fusion System in Pre-procedure Planning for Radiofrequency Ablation
To prospectively evaluate the technical success rate of real-time computed tomography/CT/magnetic resonance imagingMR and -ultrasound (CT/MRI-US) automatic fusion system and the long-term therapeutic efficacy of radiofrequency…
- Trial name
- NCT04844112
- Testing
- automatic CT/MRI-US fusion system guided radiofrequency ablation
- Volunteers
- 139 people
- Sponsor
- Seoul National University Hospital
HCC
Pembrolizumab in Hepatocellular Carcinoma
This is a single-arm Phase II trial of pembrolizumab in patients with hepatitis B virus-related hepatocellular carcinoma with parallel study on baseline and serial change in the immune environment.
- Trial name
- NCT03419481
- Testing
- pembrolizumab
- Where
- Hong Kong
- Volunteers
- 30 people
- Sponsor
- CCTU
Hepatocellular Cancer
Study of Postoperative 3D-CRT/IMRT in Hepatocellular Carcinoma
Hepatectomy is difficult when the tumor is adjacent to the big vessels of the liver and some patients can not receive radical resection. Such patients have high risk of recurrence.
- Trial name
- NCT01456156
- Testing
- postoperative radiotherapy
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Chinese Academy of Medical Sciences
Hepatocellular Carcinoma, Radiotherapy
Phase II Study of Moderate-dose Hypofractionated RT Combined With Tislelizumab for HCC With Diffuse Tumor Thrombosis
This is a single-center, single-arm, open-label study that includes patients meeting the inclusion criteria (liver-GTV volume < 700ml or estimated liver-GTV V5 < 300ml) with hepatocellular carcinoma with diffuse tumor thrombosis…
- Conditions
- Hepatocellular Carcinoma, Radiotherapy, Tislelizumab, Tumor Thrombosis
- Trial name
- NCT06233981
- Testing
- Moderate-dose Hypofractionated Intensity-modulated Radiotherapy, Tislelizumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Hepatocellular Carcinoma
The Synergistic Effect of Portal Venous Supply Control and Immunotherapy in Hepatocellular Carcinoma
Hepatocellular carcinoma is one of the most common solid malignant tumors. The prognosis of unresectable hepatocellular carcinoma is very poor.
- Trial name
- NCT05760430
- Testing
- PVE+cTACE+Camrelizumab+Apatinib, cTACE+Atirizumab+Bevacizumab
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Liver Cirrhosis, Hepatitis B
Prevention of HCC Using Mobile Phone Applications
This prospective cohort study is initiated to evaluate the compliance improvement to the standardized follow-up and clinical management in the population of compensatory hepatitis B cirrhosis with a mobile health application…
- Trial name
- NCT05094869
- Testing
- Use of mobile health application, Online interaction, Self follow-up reminders
- Volunteers
- 8,000 people
- Sponsor
- Beijing Friendship Hospital
Liver Cancer
RadioEmbolization for the ADvancement of Y90 Glass Microspheres Registry
This study is a non-interventional, observational, prospective, and global participant data registry. The study will collect effectiveness and safety data from approximately 1000 participants with liver cancers treated with…
- Trial name
- READ90Y (NCT03516695)
- Testing
- TheraSphere®
- Where
- 8 sites in United States, Canada
- Volunteers
- 95 people
- Sponsor
- Boston Scientific Corporation
Liver Tumors
The Efficacy of Chlorhexidine Gluconate Pre - Disinfection Scrubbing in Preventing Surgical Site Infections for Hepatectomy Patients
To test whether pre - disinfection skin scrub with 4% chlorhexidine gluconate is more effective on the reduction of surgical site microbial colonization and subsequent infection than is normal saline.
- Trial name
- NCT01782573
- Testing
- Chlorhexidine gluconate, 0.9% Sodium Chloride
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- Changhua Christian Hospital
Advanced Hepatocellular Carcinoma
Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC
The purpose of this study of capmatinib (INC280) and spartalizumab (PDR001) was to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of spartalizumab administered…
- Trial name
- NCT02795429
- Testing
- Spartalizumab, Capmatinib
- Where
- 17 sites in Canada, China and 6 more
- Volunteers
- 89 people
- Sponsor
- Novartis Pharmaceuticals
Liver Cancer
Single Session Combined Locoregional Therapies for Hepatocellular Carcinoma
Hepatocellular carcinoma is the third most common cause of cancer-related mortality. In recent years, transarterial chemoembolization, radio frequency ablation and microwave ablation have been accepted as treatment modalities for…
- Trial name
- NCT02646137
- Testing
- Transarterial chemoembolization (TACE), Radiofrequency ablation combined with TACE, Microwave ablation combined with TACE
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Sherief Abd-Elsalam
Hepatocellular Carcinoma
Dose Escalation Trial of Tefinostat for Cancer Associated Inflamation in Hepatocellular Carcinoma (HCC)
This study is being carried out to assess the best dose of a new drug, called tefinostat, in treating liver cancer. Tefinostat is a new drug that blocks enzymes called histone deacetylases (pronounced dee-as-et-isle-azes).
- Trial name
- CHR-2845 (NCT02759601)
- Testing
- Tefinostat
- Where
- 4 sites in United Kingdom
- Volunteers
- 69 people
- Sponsor
- Queen Mary University of London
Hepatocellular Carcinoma, Biliary Tract Neoplasms
Primary Hepatobiliary Cancer Cohort of Central China
This registry is designed as a longitudinal cohort study of patients diagnosed with primary hepatobiliary cancer in Tongji Hospital, Wuhan.
- Trial name
- CCGLC-002 (NCT05520801)
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Tongji Hospital
Hepatocellular Carcinoma Non-resectable
Lenvatinib Plus DEB-TACE With/Without FOLFOX-HAIC for Large HCC With PVTT
This multicenter retrospective study evaluated consecutive patients with large HCC and PVTT who received lenvatinib plus DEB-TACE with/without FOLFOX-HAIC between July 2019 and June 2021.
- Trial name
- NCT06265883
- Testing
- Len+DEB-TACE+HAIC, Len+DEB-TACE
- Where
- China
- Volunteers
- 205 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8
Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events
This clinical trial studies if enhanced outpatient symptom management with telemedicine and remote monitoring can help reduce acute care visit due to chemotherapy-related adverse events.
- Conditions
- Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8
- Trial name
- NCT05038254
- Testing
- Best Practice, Patient Monitoring, Questionnaire Administration
- Where
- United States
- Volunteers
- 750 people
- Sponsor
- M.D. Anderson Cancer Center
Hepatic Tumors
Prediction of Complications in Hepatic Tumors
Liver failure is one of the most severe complications in patients undergoing liver surgery for hepatic malignancies. However, it can be predicted through preoperative assessment of liver function.
- Trial name
- NCT07358975
- Testing
- [99mTc] Tc-GSA SPECT/CT
- Where
- Denmark
- Volunteers
- 192 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Hepatocellular Carcinoma, Chemoembolization, Therapeutic
Contrast-enhanced Ultrasound Evaluation of Chemoembolization
The primary objective of this trial is to evaluate the sensitivity and specificity of 2D and 4D contrast enhanced ultrasound for monitoring transarterial chemoembolization (TACE) response 1-2 weeks and 1 month post treatment as…
- Trial name
- NCT02764801
- Testing
- Ultrasound contrast agent (Contrast-enhanced ultrasound), Logiq E9 Scanner (Contrast-enhanced ultrasound)
- Where
- 3 sites in United States
- Volunteers
- 131 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Hepatocellular Carcinoma
Stiffness Measurement of Liver Tumors and Visceral Parenchyma
The investigators are measuring hepatocellular carcinoma(HCC)stiffness using Acoustic Radiation Force Impulse (ARFI) technique to enhance the diagnostic accuracy for HCC stratifications and treatment efficacy.
- Trial name
- NCT01343212
- Testing
- stiffness measurement using ARFI
- Where
- Taiwan
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- China Medical University Hospital
Recurrent Hepatocellular Carcinoma
Efficacy Analysis of Complete Laparoscopic Resection of Recurrent Hepatocellular Carcinoma
This study is aiming to evaluate the clinical efficacy of complete laparoscopic resection of recurrent hepatocellular carcinoma (HCC).
- Trial name
- NCT02613156
- Testing
- laparoscopic resection
- Volunteers
- 25 people
- Sponsor
- Sun Yat-sen University